Trials / Completed
CompletedNCT00538694
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | daptomycin |
Timeline
- Start date
- 2000-10-31
- Primary completion
- 2001-09-30
- Completion
- 2001-09-30
- First posted
- 2007-10-03
- Last updated
- 2019-11-14
Source: ClinicalTrials.gov record NCT00538694. Inclusion in this directory is not an endorsement.